Biosimilar News: FDA Approves Simlandi as Third Interchangeable Humira Biosimilar
The U.S. Food and Drug Administration (FDA) has approved Alvotech’s SIMLANDI (adalimumab-ryvk) injection as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. SIMLANDI is the first high-concentration, citrate-free […]